Paxlovid: Mechanism of Action, Synthesis, and In Silico Study
M Marzi, MK Vakil, M Bahmanyar… - BioMed Research …, 2022 - Wiley Online Library
In this work, the discovery and description of PF‐07321332, a major bioavailable oral SARS‐
CoV‐2 protease inhibitor with in vitro human coronavirus antiviral activity, and excellent …
CoV‐2 protease inhibitor with in vitro human coronavirus antiviral activity, and excellent …
The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce …
RP Joyce, VW Hu, J Wang - Medicinal Chemistry Research, 2022 - Springer
The rapid development of effective vaccines to combat the SARS-CoV-2 virus has been an
effective counter measure to decrease hospitalization and the mortality rate in many …
effective counter measure to decrease hospitalization and the mortality rate in many …
COVID‐19 in early 2023: Structure, replication mechanism, variants of SARS‐CoV‐2, diagnostic tests, and vaccine & drug development studies
Abstract Coronavirus Disease‐19 (COVID‐19) is an infectious disease caused by severe
acute respiratory syndrome‐coronaviruses‐2 (SARS‐CoV‐2), a highly pathogenic and …
acute respiratory syndrome‐coronaviruses‐2 (SARS‐CoV‐2), a highly pathogenic and …
Drugs for COVID-19: An update
J Ceramella, D Iacopetta, MS Sinicropi, I Andreu… - Molecules, 2022 - mdpi.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was the seventh
known human coronavirus, and it was identified in Wuhan, Hubei province, China, in 2020. It …
known human coronavirus, and it was identified in Wuhan, Hubei province, China, in 2020. It …
Simultaneous green TLC determination of nirmatrelvir and ritonavir in the pharmaceutical dosage form and spiked human plasma
Quantitative analysis of pharmaceutical compounds up to Nano gram levels is highly
recommended to introduce feasible and sensitive tool for determination of the compounds in …
recommended to introduce feasible and sensitive tool for determination of the compounds in …
Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID‐19: A systematic review and meta‐analysis
This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …
Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
The success of inhibitor-based therapeutics is largely constrained by the acquisition of
therapeutic resistance, which is partially driven by the undruggable proteome. The …
therapeutic resistance, which is partially driven by the undruggable proteome. The …
The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial
W Zhong, X Jiang, X Yang, T Feng, Z Duan… - Frontiers in …, 2022 - frontiersin.org
Objective: To evaluate the efficacy of Paxlovid in treating Chinese elder patients infected
with SARS-CoV-2 omicron variants. Methods: We performed a non-randomized, controlled …
with SARS-CoV-2 omicron variants. Methods: We performed a non-randomized, controlled …
Adjusted green HPLC determination of nirmatrelvir and ritonavir in the new FDA approved co-packaged pharmaceutical dosage using supported computational …
The greening of analytical methods has gained interest in the quantitative analysis field to
reduce environmental impact and improve safety health conditions for analysts. Nirmatrelvir …
reduce environmental impact and improve safety health conditions for analysts. Nirmatrelvir …
Real-world experience of the comparative effectiveness and safety of molnupiravir and nirmatrelvir/ritonavir in high-risk patients with COVID-19 in a community setting
Y Mutoh, T Umemura, T Nishikawa, K Kondo, Y Nishina… - Viruses, 2023 - mdpi.com
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …
patients with the 2019 coronavirus (COVID-19). However, little is known about their …